Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3724 in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2019-001073-86Phase 2Terminated
- Sponsor
- Molecular Templates, Inc.
- Start
- Aug 2019
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MT-3724 in diffuse large B-cell lymphoma (DLBCL), sponsored by Molecular Templates, Inc. Primary endpoint: Efficacy of MT-3724 as monotherapy in relapsed or refractory DLBCL. Started Aug 2019; status: terminated.
02
Drugs
MT-3724
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2019-001073-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001073-86.